Keyword: Remicade

Stelara

10. Stelara

Johnson & Johnson's stalwart immunology blockbuster Stelara has been a steady earner for years. But with some areas of its portfolio lagging behind, J&J is hoping that pushing Stelara into new markets can help overcome those stumbles—and keep Stelara generating significant sales for years to come.